Abeona Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABEO Nasdaq 2836 www.abeonatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Abeona Therapeutics Inc.

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 9th, 2026 8:04 am
Insider-Favored Growth Companies To Watch February 2026 - Feb 2nd, 2026 10:35 am
3 Insider-Owned Growth Stocks For Your Watchlist - Jan 1st, 2026 10:35 am
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer - Dec 15th, 2025 5:30 am
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas - Dec 11th, 2025 5:30 am
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy - Dec 8th, 2025 5:30 am
Epidermolysis Bullosa Market Research Report 2025-2035: Abeona, Castle Creek, RHEACELL, and Chiesi Lead Innovations as Gene Therapies and Advanced Wound Care Accelerate Growth - Nov 18th, 2025 8:18 am
Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand - Nov 18th, 2025 8:16 am
ABEO: First Patient Treated with Zevaskyn® Pushed to 4Q25 Following Assay Optimization - Nov 14th, 2025 1:00 am
November 2025's High Growth Companies With Insider Influence - Nov 13th, 2025 10:36 am
Abeona Therapeutics (ABEO) Is Up 17.9% After Reporting Narrowed Losses and ZEVASKYN J-code Approval - Nov 13th, 2025 3:22 am
Abeona Therapeutics Inc (ABEO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Nov 12th, 2025 2:01 pm
Here's Why Abeona Therapeutics Popped Higher Today - Nov 12th, 2025 9:37 am
Abeona Therapeutics: Q3 Earnings Snapshot - Nov 12th, 2025 5:40 am
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates - Nov 12th, 2025 5:30 am
A Look at Abeona Therapeutics (ABEO) Valuation After CMS J-Code Approval and Ahead of Q3 Earnings - Nov 12th, 2025 12:08 am
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation - Nov 7th, 2025 5:30 am
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel) - Oct 30th, 2025 8:45 am
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs - Oct 20th, 2025 6:30 am
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program - Oct 13th, 2025 5:30 am